Protagonist Therapeutics, Inc — Director's Dealing 2018

Mar 3, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protagonist Therapeutics, Inc (PTGX)
CIK: 0001377121
Period of Report: 2018-02-28

Reporting Person: Shames Richard S. (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-02-28	Common Stock	A	6500	$0.00	Acquired	6500	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-28	Stock Option (right to buy)	$16.95	A	37500	Acquired	2028-02-27	Common Stock (37500)	Direct

Footnotes

F1: Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date.

F2: The shares underlying this option shall vest as to 25% after one year following the grant date, and the remainder will vest in equal monthly installments over the following three years.